Heterotopic Transcatheter Tricuspid Valve Replacement in a Patient With Carcinoid Heart Disease

[1]  Hayk Ghukasyan.  Hedinger Syndrome: A Rare Cardiac Manifestation of Carcinoid Syndrome , 2022, Cureus.

[2]  A. Iñíguez-Romo,et al.  Six-Month Outcomes of the TricValve® System in Patients with Tricuspid Regurgitation: TRICUS EURO Study. , 2022, JACC. Cardiovascular interventions.

[3]  D. Messika‐Zeitoun,et al.  Tricuspid Transcatheter Edge-to-Edge Valve Repair , 2022, JACC: Cardiovascular Interventions.

[4]  B. Iung,et al.  TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery , 2021, European heart journal.

[5]  J. Kellum,et al.  Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. , 2020, Journal of the American College of Cardiology.

[6]  J. Hausleiter,et al.  Interventional tricuspid valve repair after failed surgical tricuspid valve reconstruction. , 2020, The Canadian journal of cardiology.

[7]  Shao‐Wei Chen,et al.  Late Outcomes of Valve Repair Versus Replacement in Isolated and Concomitant Tricuspid Valve Surgery: A Nationwide Cohort Study , 2020, Journal of the American Heart Association.

[8]  H. Thiele,et al.  Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. , 2019, European heart journal.

[9]  S. Bolling,et al.  Development of a Risk Prediction Model and Clinical Risk Score for Isolated Tricuspid Valve Surgery. , 2018, The Annals of thoracic surgery.

[10]  J. Hausleiter,et al.  Interventional Treatment of Severe Tricuspid Regurgitation: Early Clinical Experience in a Multicenter, Observational, First-in-Man Study , 2018, Circulation. Cardiovascular interventions.

[11]  H. Figulla,et al.  Transcatheter interventions for tricuspid regurgitation - heterotopic technology: TricValve. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  P. Pellikka,et al.  Early and Late Outcomes of Surgical Treatment in Carcinoid Heart Disease. , 2015, Journal of the American College of Cardiology.

[13]  A. Taylor,et al.  Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRI , 2010, Circulation. Cardiovascular imaging.

[14]  A. Schapira,et al.  Drug-induced fibrotic valvular heart disease , 2009, The Lancet.

[15]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[16]  I. Modlin,et al.  An analysis of 8305 cases of carcinoid tumors , 2000, Cancer.

[17]  K. Öberg,et al.  Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. , 1988, Circulation.

[18]  A. Maznyczka.  Circulation: Cardiovascular Interventions , 2020 .